Experimental Biology 2021 Press Materials Available Now

Embargoed press materials are now available for the virtual Experimental Biology (EB) 2021 meeting, featuring cutting-edge multidisciplinary research from across the life sciences. EB 2021, to be held April 27–30, is the annual meeting of five scientific societies bringing together thousands of scientists and 25 guest societies in one interdisciplinary community.

Read more

Researchers Identify New Role for Immune-Boosting Protein “STING” in Treatment of Head and Neck Cancer

In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING. STING has traditionally been implicated in the immune response to DNA damage, however, in this study, the focus is on STING’s role in the tumor DNA damage response.

Read more

Researchers Discover Common Mechanism Causing Autoimmune Disease and Blood Cancers

In a study by Yale Cancer Center, researchers report on the discovery of a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL).

Read more

University of Colorado Inter-campus Collaboration Wins R01 Award for Salivary Gland Cancer

Two University of Colorado Cancer Center researchers have received a five-year R01 Award for $497,893 per year from the National Institutes of Health (NIH) to study a potential new drug treatment for salivary gland cancer. The award is part of an inter-campus collaboration between Antonio Jimeno, MD, PhD, co-leader of the Developmental Therapeutics Program, and Tin Tin Su, PhD, co-leader of the Molecular and Cellular Oncology Program.

Read more

Biomarker Could Help Identify Difficult-to-Diagnose Kidney Cancer Subtype

High expression levels of the gene TRIM63 can serve as an accurate and sensitive biomarker of a subtype of kidney cancer known as microphthalmia-associated transcription factor family aberration-associated renal cell carcinomas — or MiTF renal cell carcinoma.

It’s important to distinguish MiTF from other subtypes of kidney cancers — clear cell, papillary and chromophobe — because these tumors may not respond well to standard, front-line treatments and may respond better to other approaches.

Read more

Increase your Awareness of Head and Neck Cancers

Accounting for approximately four percent of all cancers nationwide according to the National Cancer Institute, head and neck cancer is the term used to describe a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses and mouth. Even though these cancers are not as prevalent as others, everyone should be aware of risk factors and symptoms.

Read more

Improving the Precision of Treatment for Cancer Patients Receiving Radiation

Valley-Mount Sinai Comprehensive Cancer Care — part of Ridgewood, NJ, based Valley Health System — is now using new technology to improve the precision of radiation therapy by accounting for the continual motion of a patient’s anatomy so treatment is delivered with greater accuracy and effectiveness.

Valley is the only hospital on the east coast and, only fourth in the nation, using the latest generation of capabilities available in the newest iteration of ExacTrac Dynamic from Brainlab.

Read more

Surgical Technique May Reduce Positive Margin Rate in Breast Cancer Patients with DCIS

According to the American Cancer Society, a noninvasive breast cancer called ductal carcinoma in situ (DCIS) accounts for approximately one of every four new breast cancer cases in the United States. If left untreated, DCIS has the potential to evolve into invasive cancer, so many patients choose to have breast-conserving surgery or mastectomy after a diagnosis.

Read more